Fennec Pharmaceuticals shared a corporate update for shareholders and released its second quarter financial report.

Fennec Pharmaceuticals (TSX:FRX) (OTCQB:FENCF) shared a corporate update for shareholders and released its second quarter financial report.
As quoted in the press release:

“As we look forward to the second half of 2017, the pending SIOPEL 6 results have the potential to mark a significant milestone for the Company as we continue our commitment towards serving an unmet medical need for pediatric patients with cisplatin chemotherapy,” stated Rosty Raykov, CEO of Fennec. “We are pleased to have completed the $7.6 million financing which ensures that the Company has the financial flexibility to continue to focus on our internal plan for the preparation of regulatory submissions pending favorable SIOPEL 6 results.”
Development Milestones for 2017:
Final results from SIOPEL 6 in Q4 2017
Preparation for NDA/MAA submissions
Plan for commercialization

Click here to read the full press release.

Source: www.marketwired.com

chemotherapy corporate update fennec pharmaceuticals financial report financing nda patients Pharmaceutical Investing